The combination of trastuzumab deruxtecan with pertuzumab can delay cancer growth for longer than the current standard of care in people with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer, according to data from the phase 3 DESTINY-Breast09 clinical trial, presented By Dr Sara Tolaney at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The current first-line treatment for people with locally advanced or metastatic HER2-positive breast cancer is a taxane given in combination with the HER2-targeted therapy drugs trastuzumab and pertuzumab.
This treatment is known as THP and has been the standard of care for more than 20 years. However, most patients who receive THP experience cancer growth within 2 years of treatment.
Trastuzumab deruxtecan (Enhertu) is a type of HER2-targeted therapy called an antibody-drug conjugate that is made up of trastuzumab attached to deruxtecan, a chemotherapy drug. Trastuzumab deruxtecan has shown promise as a treatment for metastatic breast cancer that has progressed after earlier treatments no longer work. In the DESTINY-Breast09 clinical trial, researchers wanted to learn if trastuzumab deruxtecan could also improve outcomes for patients in the first-line setting.
The study included 1,157 patients with HER2-positive locally advanced or metastatic breast cancer who had not received treatment with chemotherapy or HER2-targeted therapy.
The patients were randomly assigned to receive either trastuzumab deruxtecan with a placebo (387 patients), trastuzumab deruxtecan with pertuzumab (383 patients), or THP (387 patients). However, at the time of this initial analysis, the researchers are presenting data only from the trastuzumab deruxtecan with pertuzumab group and the THP group.
Among the patients in these two groups, 52% had de novo disease where the cancer had already spread to other parts of the body at the time of diagnosis, 54% had hormone receptor (HR)-positive cancer, and 48% had disease that recurred after treatment in the early-stage setting. About half the patients in both groups were from Asia, and most patients were younger than 65.
Key Findings
At a median follow-up of nearly 2.5 years (29 months), the study found that:
Both groups experienced similar rates of serious side effects. However, the length of treatment was longer in the trastuzumab deruxtecan group, and certain side effects, including nausea, vomiting, and constipation, were more common in this group. Interstitial lung disease, a known side effect of trastuzumab deruxtecan, occurred in about 12% of patients in this group. However, most of these cases were not severe.
“The DESTINY-Breast09 trial has the potential to establish a new first line standard of care for metastatic HER2-positive breast cancer, a setting which hasn’t seen significant innovation in more than a decade. Trastuzumab deruxtecan represents a highly effective targeted therapy and has demonstrated promising outcomes in both the front-line and late-line HER2-positive metastatic breast cancer settings,” said lead study author Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, Massachusetts.
“The findings from Destiny-Breast09 represent a new first line standard treatment option for HER-2 positive metastatic breast cancer. The duration of therapy can now be measured in years and gives us the opportunity to look at appropriate sequencing of this new standard to optimize quality of life and toxicities,” said Rebecca Dent, MD, MSc, Deputy Chief Executive Officer (Clinical) at National Cancer Center Singapore and an ASCO Expert in breast cancer.
The study will continue until a final PFS analysis is done and until final overall survival is reported.
Watch the related interview here.
Source: ASCO
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.